Cancer News and Research

Latest Cancer News and Research

QIAGEN's therascreen EGFR Mutation Detection Kit receives Japanese regulatory approval

QIAGEN today announced the regulatory approval of its therascreen EGFR Mutation Detection Kit RGQ in Japan. EGFR, the epidermal growth factor receptor, has been shown to play an important role in certain cancers and is the target of many new anticancer drugs.

From QIAGEN Manchester Limited 10 Jan 2012

Researchers create prostate cancer drug delivery system

Honing chemotherapy delivery to cancer cells is a challenge for many researchers. Getting the cancer cells to take the chemotherapy "bait" is a greater challenge. But perhaps such a challenge has not been met with greater success than by the nanotechnology research team of Omid Farokhzad, MD, Brigham and Women's Hospital (BWH) Department of Anesthesiology Perioperative and Pain Medicine and Research.

10 Jan 2012

Viewpoints: Santorum's record on health care; Forcing care on the mentally ill

In Iowa, the Republican presidential contenders tried to outdo one another in attacking reproductive rights as they sought the support of caucusgoers from the religious right. In New Hampshire, where voters are less socially conservative, the candidates have focused more on economic issues.

10 Jan 2012

Personalized therapies may improve survival and QoL of patients with glioblastoma

Personalized prognostic tools and gene-based therapies may improve the survival and quality of life of patients suffering from glioblastoma, an aggressive and deadly form of brain cancer, reports a new University of Illinois study funded by the NIH National Cancer Institute.

10 Jan 2012

RUMC moves 200 patients into new 14-story hospital building

After more than seven years of planning and three years of construction, Rush University Medical Center successfully moved approximately 200 patients into the Tower, Rush's new, 14-story, state-of-the-art hospital building, located at Ashland Avenue and the Eisenhower Expressway.

10 Jan 2012

Fallujah doctors say chemicals from U.S. weapons to blame for high levels of birth defects

"While the U.S. military has formally withdrawn from Iraq, doctors and residents of Fallujah are blaming weapons like depleted uranium and white phosphorous used during two devastating U.S. attacks on Fallujah in 2004 for what are being described as 'catastrophic' levels of birth defects and abnormalities," Al Jazeera reports.

10 Jan 2012

Wolters Kluwer Health announces release of Oncology Times app for the iPad

Wolters Kluwer Health announced today the release of Oncology Times app for the iPad. Now cancer care professionals and others can access the latest oncology news and trends with the dynamic new Oncology Times app. Oncology Times is published by Lippincott Williams & Wilkins (LWW), part of Wolters Kluwer Health.

10 Jan 2012

Noise-cancelling headphones may reduce pain and anxiety of prostate biopsy

Tuning in to tune out may be just what's needed for men undergoing a prostate biopsy, according to researchers at the Duke Cancer Institute. The Duke team found that noise-cancelling headphones playing a classical melody may reduce the pain and anxiety of the often uncomfortable procedure.

9 Jan 2012

USPTO issues patent to Lixte's lead compounds for treatment of neurological diseases

Lixte Biotechnology Holdings announces that the United States Patent and Trademark Office awarded a patent for the use of lead compounds from each of two different types of drugs, protein phosphatase inhibitors and histone deacetylase inhibitors, for the potential prevention and treatment of neurodegenerative diseases.

9 Jan 2012

Neomatrix, UND partner to develop technology for early detection of breast cancer

The University of North Dakota and Neomatrix, LLC, have signed an exclusive agreement to develop technology for the early detection of breast cancer using the company's HALO Breast Pap Test device.

9 Jan 2012

Baxter submits GAMMAGARD LIQUID sBLA to FDA for treatment of MMN

Baxter International Inc. today announced that the company has submitted a supplemental biologics license application (sBLA) to the U.S. Food and Drug Administration (FDA) for approval of GAMMAGARD LIQUID 10% for the treatment of multifocal motor neuropathy.

From Baxter International Inc. 9 Jan 2012

More on the PIP breast implant scare

Model Jasmine Lennard underwent an emergency operation to replace her breast implants after discovering they contained banned silicone. The 26-year-old admits that she became ‘hysterical’ after discovering her implants came from French firm PIP, which is at the centre of a global health scare for using industrial-grade materials deemed unfit for medical use. And she believes last week’s procedure could have ‘saved my life’.

9 Jan 2012

Argentine President does not have cancer

Argentine President Cristina Fernandez had her thyroid gland removed amid fears of thyroid cancer. A detailed look at the tissues of her thyroid gland has shown no cancer authorities said Saturday.

9 Jan 2012

CINJ receives grant to support its Breast Surgery Fellowship Program

Receiving a boost to support its Breast Surgery Fellowship Program, The Cancer Institute of New Jersey has been awarded a $75,000 grant from The Breast Cancer Alliance for academic year 2012-2013.

9 Jan 2012

HDC, NeoGenomics sign worldwide licensing agreement to develop LDT

Health Discovery Corporation, a molecular diagnostics leader in the use of patent protected advanced mathematical techniques for personalized medicine, has entered into an exclusive worldwide licensing agreement with NeoGenomics, Inc. for laboratory developed tests in the Field of hematopoietic and solid tumor cancers excluding breast cancer, which was previously licensed to Quest Diagnostics and Smart Personalized Medicine and excluding cancer of the retina which was previously committed to Retinalyze, LLC.

9 Jan 2012

Sangamo BioSciences starts Phase 2 clinical studies to develop functional cure for HIV/AIDS

Sangamo BioSciences, Inc. announced today the initiation of two new Phase 2 clinical studies (SB-728-1101 and SB-728-902, Cohort 5) in its program to develop a "functional cure" for HIV/AIDS.

9 Jan 2012

Progress report on commercialization of BENLYSTA to be announced at JPMorgan Healthcare Conference

Human Genome Sciences, Inc. will today announce its priority goals for 2012 and report on progress with the commercialization of BENLYSTA (belimumab), the first approved drug for systemic lupus in 56 years, during a presentation this afternoon by H. Thomas Watkins, President and Chief Executive Officer, to financial analysts and investors at the 30th Annual JPMorgan Healthcare Conference in San Francisco.

9 Jan 2012

Merck selects Idera Pharmaceuticals' TLR agonists for evaluation, use as vaccine adjuvant candidates

Idera Pharmaceuticals, Inc. today announced that Merck, known as MSD outside the United States and Canada, has selected several novel Toll-like Receptor agonists targeted to TLR7, TLR8 or TLR9 for evaluation and use as vaccine adjuvant candidates under the companies' collaboration and license agreement.

9 Jan 2012

Presidio completes PPI-668 Phase 1a study on hepatitis C

Presidio Pharmaceuticals, Inc. announced today the successful completion of a Phase 1a dose-ranging assessment of PPI-668, a potent, pan-genotypic second-generation hepatitis C virus (HCV) NS5A inhibitor, in healthy volunteers and subsequent advancement to a Phase 1b assessment of the dose-related efficacy in hepatitis C patients.

9 Jan 2012

TRON uses Ingenuity Variant Analysis to identify cancer driver variants

Ingenuity Systems, a leading provider of information and analysis solutions for life science researchers, today announced that TRON has used Ingenuity Variant Analysis to identify cancer driver variants that inform the development of an experimental individualized RNA-based therapeutic.

9 Jan 2012

Cancer News and Research

Latest Cancer News and Research

QIAGEN's therascreen EGFR Mutation Detection Kit receives Japanese regulatory approval

Researchers create prostate cancer drug delivery system

Viewpoints: Santorum's record on health care; Forcing care on the mentally ill

Personalized therapies may improve survival and QoL of patients with glioblastoma

RUMC moves 200 patients into new 14-story hospital building

Fallujah doctors say chemicals from U.S. weapons to blame for high levels of birth defects

Wolters Kluwer Health announces release of Oncology Times app for the iPad

Noise-cancelling headphones may reduce pain and anxiety of prostate biopsy

USPTO issues patent to Lixte's lead compounds for treatment of neurological diseases

Neomatrix, UND partner to develop technology for early detection of breast cancer

Baxter submits GAMMAGARD LIQUID sBLA to FDA for treatment of MMN

More on the PIP breast implant scare

Argentine President does not have cancer

CINJ receives grant to support its Breast Surgery Fellowship Program

HDC, NeoGenomics sign worldwide licensing agreement to develop LDT

Sangamo BioSciences starts Phase 2 clinical studies to develop functional cure for HIV/AIDS

Progress report on commercialization of BENLYSTA to be announced at JPMorgan Healthcare Conference

Merck selects Idera Pharmaceuticals' TLR agonists for evaluation, use as vaccine adjuvant candidates

Presidio completes PPI-668 Phase 1a study on hepatitis C

TRON uses Ingenuity Variant Analysis to identify cancer driver variants

Industry Focus eBook - Oncology (1st Edition) eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Oncology (1st Edition) eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in